Abstract

IMMUNE CONTEXTURE ANALYSIS IN POLARIX SUGGESTS RESPONSE TO POLA‐R‐CHP TREATMENT REDUCES TUMOR MICROENVIRONMENT DEPENDENCY

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
CIRCULATING TUMOR DNA (CTDNA) STATUS AND CLINICAL OUTCOMES IN PATIENTS (PTS) WITH PREVIOUSLY UNTREATED DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) IN THE POLARIX STUDY
A F Herrera ... M Trněný
Hematological oncology | VOL. 41
A F Herrera, et. al.A F Herrera ... M Trněný
01 Jun 2023
MOSUNETUZUMAB DEMONSTRATES DURABLE RESPONSES IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND ≥2 PRIOR THERAPIES: UPDATED ANALYSIS OF A PIVOTAL PHASE II STUDY
...
Hematological oncology | VOL. 41
, et. al. ...
01 Jun 2023
1983PD_PR - Comprehensive genomic profiling (CGP) of carcinoma of unknown primary origin (CUP): Retrospective molecular classification of potentially eligible patients (pts) for targeted or immunotherapy treatment (tx) using the prospective CUPISCO trial’s criteria
J.S Ross ... A Krämer
Annals of oncology : official journal of the European Society for Medical Oncology | VOL. 30
J.S Ross, et. al.J.S Ross ... A Krämer
01 Oct 2019
144P Neoadjuvant giredestrant (GDC-9545) + palbociclib (P) vs anastrozole (A) + P in postmenopausal women with oestrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+/HER2– eBC): Biomarker subgroup analysis of the randomised, phase II coopERA BC study
A Bardia ... V Quiroga Garcia
Annals of oncology : official journal of the European Society for Medical Oncology | VOL. 33
A Bardia, et. al.A Bardia ... V Quiroga Garcia
01 Sep 2022
View more papers

More From: Hematological oncology

Paper Title
Journal
Date
Author
Outcomes of therapeutic plasma exchange for the treatment of patients with multiple myeloma cast nephropathy.
Danai Dima ... Jack Khouri
Hematological oncology | VOL. 42
Danai Dima, et. al.Danai Dima ... Jack Khouri
01 Jul 2024
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow-up of a multicenter, retrospective real-world experience with 321 cases outside of controlled clinical trials.
Enrica Antonia Martino ... Concetta Conticello
Hematological oncology | VOL. 42
Enrica Antonia Martino, et. al.Enrica Antonia Martino ... Concetta Conticello
01 Jul 2024
Metabolic pathway-based subtyping reveals distinct microenvironmental states associated with diffuse large B-cell lymphoma outcomes.
Xiaohui Wang ... Hengqi Liu
Hematological oncology | VOL. 42
Xiaohui Wang, et. al.Xiaohui Wang ... Hengqi Liu
01 Jul 2024
-
-
Hematological oncology | VOL. 42
--
01 Jul 2024
View more papers